# Timothy F. Cloughesy

Source: https://onco.cc/people/timothy-cloughesy/  
OnCo record `timothy-cloughesy` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Neuro-oncologist whose neoadjuvant PD-1 trial showed immunotherapy before surgery can activate immune responses in glioblastoma.

## Summary

Timothy Cloughesy led the randomised pilot trial showing neoadjuvant pembrolizumab before surgery for recurrent glioblastoma enhances intratumoural T-cell responses and was associated with longer survival than adjuvant-only dosing, a template for window-of-opportunity trials in brain tumours. He co-led the vocimagene (Toca 511) and GBM AGILE platform trial efforts and directs neuro-oncology at UCLA.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: glioma; immunotherapy; neoadjuvant
- Role: Director, UCLA Neuro-Oncology Program
- Specialisms: Glioblastoma; Neoadjuvant immunotherapy; Targeted therapy; Clinical trial design

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Cloughesy%20TF%5BAuthor%5D%20glioblastoma

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [UCLA Jonsson Comprehensive Cancer Center](https://onco.cc/institutions/ucla-jonsson/)
- key papers: [Toca 5: a virus plus a prodrug in recurrent brain cancer, tested properly, and it did not work](https://onco.cc/key-papers/paper-cloughesy-toca5-glioma-jamaoncol-2020/)
- trials: [GBM AGILE](https://onco.cc/trials/gbm-agile/)

---
JSON: https://onco.cc/api/v1/entities/timothy-cloughesy.json